Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics ...

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian ...

Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Learn more about whether Kymera Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

The biotechnology company said it had a quarterly loss of $31 million, or 35 cents a share, compared with a loss of $48.7 million, or 59 cents a share, in the same quarter last year. Analysts polled ...